PRPH (ProPhase Labs) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


What is ProPhase Labs Forward Dividend Yield %?

ProPhase Labs PRPH -4.61% Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 1612901.61% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of ProPhase Labs is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of ProPhase Labs is 0.00%.

PRPH's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.9
* Ranked among companies with meaningful Forward Dividend Yield % only.

ProPhase Labs's Dividends per Share for the three months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

ProPhase Labs  (OTCPK:PRPH) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

ProPhase Labs Forward Dividend Yield % Related Terms

PRPH vs NSTM, IDTA, IVRO: Forward Dividend Yield % Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs Forward Dividend Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Forward Dividend Yield % falls into.


ProPhase Labs Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
ProPhase Labs (PRPH) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Forward Dividend Yield % too high?
ProPhase Labs' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, ProPhase Labs ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Forward Dividend Yield % compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 62 companies for Forward Dividend Yield %. This places ProPhase Labs in the lower half of its industry. The industry median Forward Dividend Yield % is 1.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.90, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.